For NeoGenomics use only

Solid Tumor Oncology Requisition Form

NEO GENOMICS

Phone: 866.776.5907/Fax: 239.690.4237 | Email: Client.Services@NeoGenomics.com | Order Online: NeoLink.NeoGenomics.com

The following supplemental documentation is attached: ☐ **Pathology Report** ☐ **Insurance Information** ☐ Clinical Notes ☐ Relevant Test Results

Incomplete or missing data may result in delayed testing. ***Bold fields are required.***

CLIENT INFORMATION – Required Information

Account Number **Account Name**

Street Address

City, State, Zip

Phone# **Fax#**

Req Completed By **Date** / /

Ordering Physician **NPI#**

Treating Oncologist/Physician **NPI#**

PATIENT INFORMATION

First Name / Middle Initial / Last Name

Date of Birth / /

Biological Sex ☐ M ☐ F ☐ Unknown

Street Address

City, State, Zip

Phone# *either phone or email is required* ☐ Mobile ☐ Home

Email

Medical Record # Other Patient ID#

BILLING INFORMATION – Please include face sheet and front/back of insurance card

Bill Type ☐ Medicare ☐ Insurance/Medicaid ☐ Patient Self Pay ☐ Hospital/Institution If billing charges to other Hospital/Facility:

Patient Status at Time of Specimen Collection ☐ Office/Non-Hospital ☐ Hospital Outpatient ☐ Hospital Inpatient, Date of Discharge / /

Primary Insurance Plan | Policy Holder Name

Subscriber ID | Group # | Prior Authorization #

Policy Holder DOB / / | Patient Relationship to Policy Holder ☐ Self ☐ Spouse ☐ Child Other:

CURRENT DIAGNOSIS AND RELEVANT CLINICAL HISTORY – Required Information

Date of Original Diagnosis / / | **Diagnosis** ☐ Breast ☐ Colorectal ☐ Gastric ☐ Melanoma ☐ Lung ☐ Ovarian Other:

Stage ☐ I ☐ II ☐ IIIA ☐ IIIB ☐ IV ☐ Unknown Note:

Status ☐ Initial Diagnosis ☐ Progression ☐ R/R (Relapsed/Refractory)

Primary ICD-10 Codes *(C and D codes only)*

TEST SELECTION – Full test menu at NeoGenomics.com

☐ **PanTracer™ Pro**: (DNA/RNA NGS with cancer type directed IHC and ancillary testing based on the patient's tumor type)*

☐ Include PanTracer LBx for reflex if tissue is insufficient for NGS

OR – Select individual tests:
PanTracer Comprehensive Genomic Profiling of 500+ genes by NGS

☐ **PanTracer LBx** (Liquid biopsy)
☐ PanTracer LBx - Extract and Hold

☐ **PanTracer Tissue** (FFPE tumor profiling)
☐ Reflex to PanTracer LBx if tissue is insufficient for NGS

☐ **PanTracer Tissue + HRD** (FFPE tumor profiling for Ovarian)
☐ Reflex to PanTracer LBx if tissue is insufficient for NGS

Add-On Therapy Selection IHC testing with PanTracer Tissue

☐ PD-L1 22C3
☐ ALK D5F3 (NSCLC)
☐ c-MET CDx (NSCLC)
☐ FOLR1 (Ovarian)
☐ Claudin18 (Gastric)
☐ HER2 Gastric/GEA
☐ HER2 Breast
☐ HER2 Other (Gastric Scoring)†
☐ HER2 Other (Breast Scoring)†
☐ Mismatch Repair (MMR) Panel

Focused Testing Panels: Additional options relevant to specific indications

☐ **NeoTYPE® DNA & RNA - Brain** (DNA/RNA NGS and FISH)
☐ PD-L1 LDT IHC
☐ MGMT Promoter Methylation Analysis

☐ **Sarcoma Comprehensive NGS Fusion Panel** (RNA NGS)
☐ **Early-Stage NSCLC Panel** (EGFR, ALK, ROS1, PD-L1 22C3)
☐ **CancerTYPE ID** for unknown/uncertain tumor type with Pathologist-directed NGS testing

Other:

TISSUE SPECIMEN RETRIEVAL INFORMATION

Hospital / Pathology Lab Name Physician is requesting a specific specimen Specimen ID:

Address, City, State, Zip **Phone#** **Fax#**

Body site of biopsy **Collection Date:** / / ☐ Primary ☐ Metastatic ☐ Unknown

For molecular/NGS testing, if NeoGenomics retrieves multiple blocks, our pathologists will combine as necessary unless alternative instructions are provided below.

BLOOD SPECIMEN INFORMATION – The patient's phone number or email address is required for mobile phlebotomy

☐ Mobile Phlebotomy Request OR ☐ Shipping Specimen Specimen ID: **Collection Date:** / /

Special Specimen Instructions

PHYSICIAN SIGNATURE and CONSENT – Required Information

Ordering Physician Signature **Printed Name** **Date** / /

My signature certifies that (1) I am the patient's treating physician and am authorized under applicable law to order the tests on this test requisition, (2) each test ordered on this test requisition is medically necessary for the patient, (3) the results of each test will inform the patient's ongoing treatment plan and will be used in the management of the patient's care, (4) I explained to the patient the nature and purpose of each test to be performed pursuant to this test requisition, including, but not limited to, the purpose, capabilities, limitations, benefits and risks of each test, and the patient has had the opportunity to ask questions regarding each test and the collection, use, and disclosure of his/her samples and data, (5) I obtained from the patient all consents and authorizations required by applicable state and federal laws for the performance and billing of the ordered tests, which I will maintain on file and provide to NeoGenomics upon request, and (6) my decision to order these tests is not conditioned on, and was not influenced by, any remuneration, incentive, or other pecuniary benefit offered or provided by NeoGenomics or any third party, whether directly or indirectly.

Neo PanTracer LBx Liquid Biopsy Certification: If ordering Neo PanTracer LBx, the undersigned additionally certifies that he/she understands Medicare's medical necessity criteria for the Neo PanTracer LBx Liquid Biopsy test listed on the back of this form.

**Provided diagnosis will determine additional, appropriate testing for the case. See NeoGenomics.com/pantracer-portfolio#pro for associated add-ons by cancer diagnosis*

Solid Tumor Oncology Requisition Form

Additional Billing Information: Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

1. **Binding Service Order.** This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
2. **Third-Party Billing by NeoGenomics and Right to Bill Client.** Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state, or commercial health insurer or other third-party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event that NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten (10) days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Neo PanTracer™ LBx Conditions for Medicare Coverage Neo PanTracer LBx is a plasma-based, somatic comprehensive genomic profiling test (CGP) intended to assist physicians caring for patients with advanced solid tumors. In accordance with Medicare's MolDX Noridian LCD L39230, testing is appropriate under the following circumstances:

- Patient has been diagnosed with a recurrent, relapsed, refractory, metastatic, or advanced solid tumor that did not originate from the central nervous system. Patients who would meet all the indications on the Food and Drug Administration (FDA) label for larotrectinib if they are found to have a neurotrophic receptor tyrosine kinase (NTRK) mutation may be considered to have advanced cancer, and
- For a patient who has been tested previously using a cell-free DNA/liquid biopsy test on the same genetic content, that patient may not be tested again unless there is clinical evidence that the cancer has evolved wherein testing would be performed for different genetic content. For example, in patients with cancer who were previously tested using a cell-free DNA/liquid biopsy test, if there is evidence for recurrence or progression despite response to a prior therapy, that recurrence or progression may represent a change in the tumor's molecular profile and may constitute a new clinical indication for additional genetic testing, and;
- Patient is untreated for the cancer being tested, or the patient is not responding to treatment (e.g., progression or new lesions on treatment), and;
- The patient has decided to seek further cancer treatment with the following conditions:
  - The patient is a candidate for further treatment with a drug that is either FDA-approved for that patient's cancer, or has a National Comprehensive Cancer Network (NCCN) 1 or NCCN 2A recommendation for that patient's cancer, and
  - The FDA-approved indication or NCCN recommendation is based upon information about the presence or absence of a genetic biomarker tested for in the Neo PanTracer LBx, and;
- Tissue-based, comprehensive genomic profiling (CGP) is infeasible (e.g., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated) or specifically in NSCLC Tissue-based CGP has shown no actionable mutations.

A patient signed ABN is required if patient does not meet the coverage criteria. ABN is also required if ordering Neo PanTracer LBx concurrently with tissue testing that includes EGFR, BRAF, ALK, and ROS1.

Specimen Requirements and Usage: NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.

PanTracer LBx: Peripheral blood: Two x 10 mL Streck Cell-Free DNA BCT® tubes. Do not refrigerate. Special collection tubes and shipping requirements apply.

PanTracer LBx: Extract and Hold: ctDNA will be isolated from plasma and stored in freezer. PanTracer LBx analysis is not performed until the client test order is received. Processed samples will be retained for 90 days.

For molecular/NGS tissue testing, the following is requested: A single block for large resections where tumor is abundant, or up to 4 blocks from procedures with smaller specimens (e.g. core biopsy, cell block). Only blocks from the same procedure and same tumor should be submitted together.

All other tests: Refrigerate specimen if not shipping immediately and use cool pack during transport. A block is preferred for testing; please see individual test webpages for specimen requirements.

Please call our Client Services team with questions regarding specimen requirements or shipping instructions at 866.776.5907, option 3. Please refer to **NeoGenomics.com** for specific details on each specimen.

PanTracer Tissue and NeoTYPE® DNA and RNA – Brain Profiles: If the sample is insufficient to produce either DNA or RNA results, the available results will be reported and alternate CPT® Codes may apply.

CancerTYPE ID® with reflex to pathologist directed NGS cancer profile determined by the CancerTYPE ID result. CancerTYPE ID will be performed, reported, and billed separately by Biotheranostics, Inc. For comprehensive details about CancerTYPE ID including test description, intended use, and limitations, visit **CancerTypeID.com.**

†**HER2 Other – Breast & Gastric Scoring:** Most non-breast, non-gastroesophageal primary tumors lack consensus guidelines for HER2 interpretation. In these situations, the CAP advises applying both modified breast scoring (relevant for trastuzumab eligibility) and gastric scoring (relevant for fam-trastuzumab deruxtecan-nxki) in endometrial serous adenocarcinoma and other gynecologic malignancies. For non-breast, non-gastric/GEJ tumors being evaluated specifically for fam-trastuzumab deruxtecan-nxki under its so-called "pan-tumor" indication, gastric scoring is recommended. Gastric scoring is also used for biliary tract cancers. Outside of these therapy-driven contexts, no consensus exists on which scoring system should be applied. Breast scoring is the default approach if not specified.

Test Descriptions: For our complete test menu, turnaround times, specimen requirements, and more, please visit **NeoGenomics.com/Test-Menu.**